Linked Life Data

11104552

Source:http://linkedlifedata.com/resource/pubmed/id/11104552

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11104552rdf:typepubmed:Citationlld:pubmed
pubmed-article:11104552lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0205208lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0205464lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C1709060lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0031610lld:lifeskim
pubmed-article:11104552lifeskim:mentionsumls-concept:C0539090lld:lifeskim
pubmed-article:11104552pubmed:issue12lld:pubmed
pubmed-article:11104552pubmed:dateCreated2001-1-9lld:pubmed
pubmed-article:11104552pubmed:abstractTextCT-2584 HMS, 1-(11-dodecylamino-10-hydroxyundecyl)-3, 7-dimethylxanthine-hydrogen methanesulphonate, is a modulator of intracellular phosphatidic acid. We treated 30 patients as part of a Phase I and pharmacokinetic study to determine the maximum-tolerated dose of CT-2584 HMS, toxicity profiles, pharmacokinetic profile and antitumour effects at escalating dose levels. CT-2584 HMS was given as a continuous infusion for 6 hours for 5 consecutive days every 3 weeks. Plasma samples for pharmacokinetic studies were analysed using a validated high-performance liquid chromatographic assay. Mean C(max)and AUC values for each dose group were similar on days 1 and 5 and increases in plasma concentration (C(max)and AUC) appeared proportional to the dose. CT-2584 HMS had a mean elimination half-life of 7.3 hours. Values of V(d)and clearance were independent of dose and duration of treatment. Dose escalation was halted at 585 mg/m(2)because of malaise and lethargy, which was sometimes accompanied by nausea and headache. 26 patients were evaluable for response, one patient with pleural mesothelioma achieved a partial response to treatment confirmed by CT scanning. A dose level of 520 mg/m(2)daily x 5 days would be suitable for Phase II testing. Alternative schedules of CT-2584 HMS to overcome the limiting toxicity of malaise would be worthy of examination.lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:languageenglld:pubmed
pubmed-article:11104552pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:citationSubsetIMlld:pubmed
pubmed-article:11104552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11104552pubmed:statusMEDLINElld:pubmed
pubmed-article:11104552pubmed:monthDeclld:pubmed
pubmed-article:11104552pubmed:issn0007-0920lld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:GardnerCClld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:DickensDDlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:JongB BBBlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:RansonMMlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:McGownAAlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:GumbrellLLlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:BrannanMMlld:pubmed
pubmed-article:11104552pubmed:authorpubmed-author:CheesemanS...lld:pubmed
pubmed-article:11104552pubmed:copyrightInfoCopyright 2000 Cancer Research Campaign.lld:pubmed
pubmed-article:11104552pubmed:issnTypePrintlld:pubmed
pubmed-article:11104552pubmed:volume83lld:pubmed
pubmed-article:11104552pubmed:ownerNLMlld:pubmed
pubmed-article:11104552pubmed:authorsCompleteYlld:pubmed
pubmed-article:11104552pubmed:pagination1599-606lld:pubmed
pubmed-article:11104552pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:meshHeadingpubmed-meshheading:11104552...lld:pubmed
pubmed-article:11104552pubmed:year2000lld:pubmed
pubmed-article:11104552pubmed:articleTitlePhase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours.lld:pubmed
pubmed-article:11104552pubmed:affiliationCRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.lld:pubmed
pubmed-article:11104552pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11104552pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11104552pubmed:publicationTypeClinical Trial, Phase Illd:pubmed